Morningstar

AstraZeneca and Daiichi Sankyo's Datroway Shows Meaningful Improvement for Breast Cancer Patients

Provided by Dow Jones Oct 6, 2025, 7:10:00 AM

By Adam Whittaker

AstraZeneca and Daiichi Sankyo's Datroway drug showed statistically significant and clinically meaningful improvement for patients with breast cancer in late-stage trials, the companies said.

The drug was tested on patients with metastatic triple-negative breast cancer for whom immunotherapy wasn't an option, the companies said.

The data showed it delivered a clinically meaningful improvement for both progression-free survival and overall survival.

The safety profile was consistent with previous clinical trials of Datroway in treating breast cancer, the companies said. The data will be presented at an upcoming medical meeting and shared with regulatory authorities, they add.

Datroway is also used to treat lung cancer.

Write to Adam Whittaker at adam.whittaker@wsj.com

(END) Dow Jones Newswires

October 06, 2025 03:10 ET (07:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Stocks to Buy Before They Rise Further

Plus, the member of the triple-digit club reporting earnings this week.

David Sekera, CFA and Susan Dziubinski Sep 28, 2026

2 Undervalued Stocks to Buy Before They Rebound

These wide-moat stocks look attractive after their recent pullbacks.

Susan Dziubinski Sep 29, 2026

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.

Tori Brovet Oct 1, 2026

The 10 Best Dividend Stocks

These are the top dividend-paying stocks to buy today.

Susan Dziubinski Sep 29, 2026

12 Best Blue-Chip Stocks to Buy for the Long Term

The stocks of these high-quality companies look cheap today.

Tori Brovet Sep 25, 2026

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.